 | Up a level |
Atkinson, Andrew; Miro, Jose M; Mocroft, Amanda; Reiss, Peter; Kirk, Ole; Morlat, Philippe; Ghosn, Jade; Stephan, Christoph; Mussini, Cristina; Antoniadou, Anastasia; Doerholt, Katja; Girardi, Enrico; De Wit, Stéphane; Kraus, David; Zwahlen, Marcel; Furrer, Hansjakob (2021). No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL. Journal of the International AIDS Society, 24(6), e25726. BioMed Central 10.1002/jia2.25726
The Collaboration of, Observational HIV Epidemiological Research; Lewden, Charlotte; Bouteloup, Vincent; De Wit, Stéphane; Sabin, Caroline; Mocroft, Amanda; Wasmuth, Jan Christian; van Sighem, Ard; Kirk, Ole; Obel, Niels; Panos, George; Ghosn, Jade; Dabis, François; Mary-Krause, Murielle; Leport, Catherine; Perez-Hoyos, Santiago; Sobrino-Vegas, Paz; Stephan, Christoph; Castagna, Antonella; Antinori, Andrea; ... (2012). All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration{dagger}. International journal of epidemiology, 41(2), pp. 433-45. Oxford: Oxford University Press 10.1093/ije/dyr164
Opportunistic Infections Project Team of the, Collaboration of Ob; Mocroft, Amanda; Reiss, Peter; Kirk, Ole; Mussini, Cristina; Girardi, Enrico; Morlat, Philippe; Stephan, Christoph; De Wit, Stephane; Doerholt, Katja; Ghosn, Jade; Bucher, Heiner C; Lundgren, Jens D; Chene, Genevieve; Miro, Jose M; Furrer, Hansjakob (2010). Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clinical infectious diseases, 51(5), pp. 611-9. Cary, N.C.: Oxford University Press 10.1086/655761
